title: A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs.
abstract: We present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product Lutathera (Lu-DOTA0-Tyr3-octreotate). She was resistant to more than 6 lines of therapy including all the available active drugs in soft tissue sarcomas. The high expression of somatostatin receptors was shown by microarrays and Octreoscan. The overall duration of response exceeded 1 year.
authors.affiliation: From the *Plataforma de Oncología Hospital Quirón Torrevieja, Cátedra Oncología Multidisciplinar Universidad Católica San Antonio de Murcia, Murcia, Spain; and †Advanced Accelerator Applications, New York, NY.
authors.forename: Aurora
authors.initials: A
authors.lastname: Crespo-Jara
authors.forename: Ramón
authors.initials: R
authors.lastname: González Manzano
authors.forename: Maribel
authors.initials: M
authors.lastname: Lopera Sierra
authors.forename: María Carmen
authors.initials: MC
authors.lastname: Redal Peña
authors.forename: Antonio
authors.initials: A
authors.lastname: Brugarolas Masllorens
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000378:metabolism; D013584:Sarcoma, Synovial / Q000188:drug therapy* / Q000556:secondary*; D016896:Treatment Outcome
chemical_list: C504257:177Lu-octreotide, DOTA(0)-Tyr(3)-; D000970:Antineoplastic Agents; D017481:Receptors, Somatostatin; D015282:Octreotide